Mexico Cancer Immunotherapy Market Size & Outlook

Monoclonal antibodies was the largest segment with a revenue share of 66.43% in 2023. Horizon Databook has segmented the Mexico cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.

The Mexico cancer immunotherapy market is expected to be driven by increase in the prevalence of cancer, favorable reimbursement scenario, and high consumer awareness about the disease. Several emerging and alternative cancer treatments pose a threat to the immunotherapeutic drugs in Mexico, such as laser cancer therapy, hyperthermia, DMSO potential therapy, insulation potential therapy, enzymatic cancer therapy, and oxygen therapy.

However, there is a lack of data regarding the epidemiology of cancer in Mexico as it does not have a population-based cancer registry. According to an article published in the JCO Global Oncology, the incidence of cancer in the Central and South American region is estimated to increase to 1.7 million by 2030.

Moreover, various government and nongovernment organizations are striving to create awareness of various types of cancers in Mexico. This, in turn, is expected to drive the market over the forecast period.